Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18854579 | 0.84 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL18866540 | 0.83 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3856852 | 0.83 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3860447 | 0.83 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2LNPEP | |
| SCHEMBL4264816 | 0.81 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL702653 | 0.80 | LTA4H (0.42) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL28946558 | 0.79 | SMYD2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL28946557 | 0.79 | SMYD2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL8215769 | 0.79 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL26651024 | 0.79 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | CYP3A4 1149/4885HTT 3257/4885SMN1; SMN2 2588/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | CYP3A4 1010/4885HTT 3339/4885SMN1; SMN2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.